Economic Implications of Osteoporotic Fractures in Postmenopausal Women
An American Journal of Managed Care® Supplement
This activity is supported by an educational grant from
Radius Health, Inc.
Radius Health, Inc.
Faculty
Jeenal Patel, PharmD, BCGP
Formulary Manager
WellDyne
Lakeland, Florida
Program Description
Osteoporosis is a preventable and treatable disease that most commonly occurs in postmenopausal women. However, its primary symptom of bone fragility is often not identified until there has been a trauma, such as fracture from a fall. Pharmacists must be familiar with the patient-specific risk factors associated with development of osteoporosis and can educate about prevention strategies, such as early and diagnostic screening, and provide nonpharmacologic recommendations for optimal vitamin D and calcium supplementation. This article will review several pharmacologic therapies used for the prevention and treatment of osteoporosis that pharmacists need to be familiar with to support reduction in fracture risk for their patients. Equipped with knowledge of these prevention and treatment strategies, pharmacists can be integral to developing prior authorization and step therapy processes within managed care organizations and ensuring transitions of care after a fracture.
Target audience: Managed care pharmacists
Activity type: Application
Release date: November 30, 2020
Expiration date: November 30, 2021
Estimated time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, the participant will be able to:
- Investigate the risks of osteoporosis and osteoporotic fractures in postmenopausal women
- Examine clinical data for emerging therapies for the treatment of osteoporosis in postmenopausal women
- Explore the role of managed care professionals in creating access to novel therapies for patients at risk for osteoporosis or for osteoporotic fractures
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-380-H01-P. The activity is available for CE credit through November 30, 2021.Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the online article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Jeenal Patel, PharmD, BCGP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy
According to the disclosure policy of The American Journal of Managed Care® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Disclosure of Unapproved/Off-Label Use
The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.
The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care®, Pharmacy Times Continuing Education™, or any of the companies that provided commercial support for this CE activity.
Signed disclosures are on file at the office of The American Journal of Managed Care®, Cranbury, New Jersey.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
